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Sažetak
Nakon transplantacije organa, pacijenti primaoci organa se stavljaju na režim imunosupre-
sivne terapije, a u primalaca bubrega ta terapija je doživotna. Bez obzira na poboljšanje
preživljavanja nakon transplantacije organa, brojne su komplikacije koje se mogu javiti
na kon transplantacije, a razvoj maligniteta usled imunosupresije nastavlja da bude zna ča -
jan problem. Jedan od najčešćih tipova maligniteta koji se srecé kod ovakvih pacijenata  je
limfoproliferativni poremećaj koji se verovatno razvija kao posledica pomenute imuno -
supresije. Opisan je slučaj limfoma u ileocekalnoj regiji u 45-godišnjeg muškarca sa trans-
plantiranim bubregom, koji je bio na imunosupresivnoj terapiji zasnovanoj na takroli -
musu, tokom 10 godina. Literaturni podaci ukazuju na drugačiju lokalizaciju limfoma kao
neželjene reakcije nakon dugoročnog korišćenja takrolimusa, pa je prema našim sazna -
njima, ovo jedinstven slučaj razvoja limfoma u ileocekalnoj regiji. Ozbiljne neželjene
reakcije i toksični potencijal takrolimusa naglašavaju značaj pronalaženja optimalnog
balansa između efektivne koncentracije leka i rizika vezanih za njegovu upotrebu.
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INTRODUCTION
Immunosuppressive therapy after solid organ transplan-
tation has been steadily improved over the last few decades
and due to the introduction of new immunosuppressive
agents causes of mortality among renal transplant recipients
have been changed. Nowadays, with the improvement of the
long-term graft survival mortality occurrence due to malig-
nancy has been increased with the incidence of 20% ten
years after the kidney transplantation (1). Not only do the
immunosuppressive drugs comprise defense against viral
infections that act as malignancy promoters, but they also
induce DNA damage and interfere with DNA repair mecha-
nisms (2,3). The most common types of malignancies are
skin cancer, post-transplant lymphoproliferative disease
(PTLD) that may progress to lymphoma (4, 5). An increased
incidence of malignant tumors is one of the major factors
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influencing the long-term survival of kidney transplant
patients and therefore needs to be addressed carefully. 
Here, we presented the case of plasma cell type lym-
phoma in the ileocecal region of a 45-year-old male kidney
transplant patient who was on the imunosupressive-based
regimen for ten years. Although this case report was previ-
ously described (6), this paper focused primarily on immuno-
suppressive therapy. 
CASE REPORT
The patient was 24-years-old when he underwent a uni-
lateral nephrectomy due to left kidney calculus. Chronic
insufficiency of the right kidney occurred in the following
year, and the patient was treated with hemodialysis. Two
years after nephrectomy, the patient received a transplant
from living donor. After an episode of acute rejection of the
transplanted graft, the patient was subjected to the appropri-
ate therapy and allograft function was stabilized. Initially,
patient has been on triple therapy with cyclosporine, aza-
thioprine, and prednisone, according to previous standard
transplantation practice. In 2004, the patient was converted
to a newer regimen – firstly from azathioprine to mycophe-
nolate mofetil and secondly from cyclosporine to therapy
that included tacrolimus (1mg twice a day), mycophenolate
mofetil (250 mg twice a day), and prednisone (10 mg once a
day). 
In September 2013, 20 years after the first nephrectomy,
the patient was hospitalized again, this time due to sepsis
and the signs of respiratory insufficiency. Moreover, pro-
found inflammatory syndrome, hydronephrosis, pyelo ne -
phritis and right kidney atrophy, were observed. These com-
plications precipitated the right nephrectomy in February
2014. The overall renal function was subsequently ascer-
tained by the previously transplanted kidney. Multislice
Computed Tomography (MSCT) of the abdomen showed
visualized transplanted kidney of the following dimensions -
108x52x12mm and no signs of urinary obstruction. Above
the upper half of the transplanted kidney, inter-intestinally
homogeneous collection (size 60x40mm) was observed.
Furthermore, areas of inflammation containing two formed
abscesses with hypervascularized walls of 3.5 mm thickness
were detected below the right lobe of the liver zone in the
block with associated intestinal convolutions. "Staging"
MSCT findings showed enlarged lymph node in right iliac
fossa and right femoral fossa (Figure 1). 
Surgical removal of visualized abscess collection was in -
te n ded. However, on admission, laboratory values showed
le uko cytosis (17x109/L), anaemia (erythrocytes 3.53x109/L,
hemoglobin 107g/L), elevated inflammatory markers (SE
125mm/h, CRP 188 mg/L and fibrinogen 5.6g/L), increased
urea (15.8 mmol/L) and creatinine  (231 μmol/L). After
detailed preoperative assessment and preparation, laparoto-
my with midline incision was performed. 
Additional exploration verified the existence of the block
tumor of 10 cm in diameter, at the level of terminal ileum
and cecum, accompanied with regional lymphadenopathy in
the block with an appendix. The tumor was situated above
well placed transplanted kidney without any infiltration. A
urologist confirmed the normal findings of the kidney trans-
plant and carefully removed tumor lesions with associated
lymph nodes using standard right hemicolectomy with lym-
phadenectomy. Slices of the right colon, tumor changes in
the block and lymph nodes were sent for further histopatho-
logical analysis.
Relatively well-circumscribed nodular tumor localized
in the fatty tissue of retroperitoneum spreading to the wall of
ascending colon, terminal ileum and appendix were
described. The tumor had tough, solid texture, it was capsu-
lated and clearly separated from adipose tissue (Figure 2).
Right next to the tumor nodose were two enlarged lymph
nodes measuring 25x20x15mm and 10x10x5mm in size, as
well as the unclear infiltrate of 20x20x15mm in size, similar
to a nodular tumor and located about 1 mm from the line of
fat tissue resection. From the remaining adipose tissue, 6
more lymph nodes were isolated.
Figure 1. MSCT findings showing enlarged lymph node in right iliac fossa (A) and in right femoral fossa (B).
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Histological sections of the tumor mass showed the pro-
liferative change of organization from multinodular to dif-
fuse, consisting of a relatively monomorphic population of
large cells that might correspond to atypical lymphoid cells.
The peripheral proliferation of small lymphoid cells was
observed. In described nodular areas, large blastoid cells
with various zones of necrosis, moderate mitotic index and
atypical mitosis were detected. Tumor mass consisted of
Reed-Sternberg cells which were CD15, CD30 and EBV-
positive and PAX5, CD20, CD3, CD5, BCL2, Alk1 negative
based on histopathological and immunohystochemistry find-
ings. Obtained result indicated nodular sclerosis type of
Hodgkin lymphoma. 
The postoperative course was usual, and the patient was
discharged in good general condition, metabolically and
hemodynamically stable. Treatment involved modification
of the immunosuppressive drug regimen (tacrolimus and
MMF were discontinued), resection of localized disease, and
chemotherapy.
All relevant information from the patient's history is
graphically presented in the timeline (supplementary materi-
al). 
DISCUSSION
Patient survival time after renal and other solid organ
transplantations has been substantially increased, partly due
to modern immunosuppressive treatment. Nevertheless, the
frequency of tumors is 2 to 4-fold higher when compared to
the non-transplanted population, the most prevalent being
Kaposi's sarcomas, non-Hodgkin lymphomas, and non-
melanoma skin cancers with the rate over 20 times greater
than the one in general population (7, 8). In a study that inclu -
ded 2224 solid-organ transplant recipients who underwent
transplant between 1985 and 2013, 27 of 2224 patients de -
ve loped PTLD. The mean interval between transplant and
diagnosis of PTLD was 65 months. Most patients with
PTLD have extranodal involvement, with the gastrointesti-
nal tract being the major site of clinical presentation-35% of
all cases (9). In a retrospective single-center study conducted
to assess the occurrence of de novo neoplasms in renal pati -
ents, malignancy was observed in 4.8% of patients of which
22% developed urinary tract tumors while 16% of recipients
developed non-Hodgkin lymphoma with PTLD (10).
In this case study, some interesting points have been pre-
sented. It is known that Epstein-Barr virus (EBV) plays a
major role in the development of post-transplant lymphopro-
liferative disorders, although an increasing awareness of
EBV-negative PTLD has been recently shown (11). Positive
EBV immunostain of the tumor mass observed in this partic-
ular case confirmed that PTLD and lymphomas develop-
ment in kidney transplant patients are highly correlated with
EBV infections. A long lasting scientific debate on the pos-
sible influence of immunosuppressive regimen on malignan-
cy incidence among kidney transplanted patients have point-
ed to the association between malignancy incidence and
duration of therapy rather than a particular therapy regimen
(12). Some studies report significantly lower malignancy in
recipients on tacrolimus treatment (13). In this particular
case, tacrolimus-based regimen produced malignancy devel-
opment after ten years suggesting the duration of exposure
as the more relevant factor of malignancy incidence. The
ileocecal localization of plasma cell type lymphoma
observed in this case study should be especially emphasized
since it is to our knowledge, unique in literature. 
The importance of careful monitoring of posttransplant
patients in regards to side-effects and toxicity of immuno-
suppressants is essential and emphasized through this case
report. Timely recognition and treatment may show the ben-
efit beyond survival. Serious adverse drug reactions and
potential toxicity of tacrolimus underline the importance of
finding the optimal balance between effective drug concen-
tration and the risk associated with its use.
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Figure 2. Relatively well-circumscribed nodular tumor with
tough and solid texture was excised. (Taken from Mihaljević et al,
2016) 
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supplementary material. 
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Abstract 
Following solid organ transplantation, the patient's management includes the provision of
immunosuppressive therapy to the recipient. All kidney transplant recipients require life-
long immunosuppression. Regardless the improving survival following solid organ trans-
plantation, post-transplant complications such as the development of malignancy due to
immunosuppression remain to be an issue. One of the most common malignancies encoun-
tered in the post–solid organ transplant is lymphoproliferative disorder likely developed as
a consequence of immunosuppression. We report a case of plasma cell type lymphoma in
the ileocecal region of a 45-year-old male kidney transplant patient who was on a
tacrolimus-based regimen for ten years. Although literature data indicate differently local-
ized lymphoma as an adverse reaction to the long term use of tacrolimus, to our knowl-
edge, this is the first described case of lymphoma in the ileocecal region. Serious adverse
drug reactions and potential toxicity of tacrolimus emphasize the importance of finding the
optimal balance between effective drug concentration and the risk associated with its use.
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